225. 先天性腎性尿崩症
［臨床試験数：12，薬物数：45（DrugBank：17），標的遺伝子数：30，標的パスウェイ数：63］
Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-002204-38-DK (EUCTR) | 24/11/2020 | 07/05/2020 | Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug Fluconazole | Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication | Nephrogenic diabetes insipidus MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | INN or Proposed INN: Fluconazole Other descriptive name: FLUCONAZOLE | Claus Bistrup | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 10 | Phase 2 | Denmark | ||
| 2 | JPRN-jRCTs031180369 | 12/04/2018 | 18/03/2019 | Tolvaptan for nephrogenic diabetes insipidus | Exploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation | Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus, polyuria;D018500 | Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days. | Makita Noriko | NULL | Recruiting | >= 20age old | Not applicable | Both | 3 | Japan | |
| 3 | EUCTR2016-001591-30-DK (EUCTR) | 06/11/2017 | 09/03/2017 | Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil | Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil | Nephrogenic diabetes insipidus because of AVP2R-mutation MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Odense University Hospital | NULL | Not Recruiting | Female: no Male: yes | 2 | Phase 2 | Denmark | |||
| 4 | NCT02967653 (ClinicalTrials.gov) | July 13, 2017 | 15/11/2016 | Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus | Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial | Lithium Use, Nephrogenic Diabetes Insipidus | Drug: Atorvastatin | Lady Davis Institute | NULL | Completed | 18 Years | 85 Years | All | 60 | Phase 2 | Canada |
| 5 | JPRN-UMIN000021708 | 2016/04/18 | 18/04/2016 | A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. | A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. | Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene | Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days. | Department of Nephrology and Endocrinology, The University of Tokyo Hospital | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 3 | Not selected | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02460354 (ClinicalTrials.gov) | September 2015 | 29/5/2015 | Metformin and Congenital Nephrogenic Diabetes Insipidus | Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) | Diabetes Insipidus | Drug: Metformin | Emory University | NULL | Terminated | 18 Years | N/A | Male | 2 | Phase 1 | United States |
| 7 | EUCTR2012-001809-24-NL (EUCTR) | 31/07/2013 | 06/09/2012 | A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected? | Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients | lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus) MedDRA version: 15.0;Level: LLT;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications MedDRA version: 15.0;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses Product Code: SUB21605 INN or Proposed INN: desmopressin acetate trihydrate Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE | Radboud University Nijmegen Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 8 | EUCTR2011-005970-41-NL (EUCTR) | 27/02/2012 | 08/02/2012 | The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot study | The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study | lithium-induced nephrogenic diabetes insipidus MedDRA version: 14.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Trade Name: Acetazolamide Sandoz 250 Other descriptive name: ACETAZOLAMIDE | Radboud University Nijmegen Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 9 | EUCTR2006-003360-56-DK (EUCTR) | 28/08/2009 | 07/07/2009 | Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY | Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY | Kongenit nefrogen diabetes insipidus MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Confortid INN or Proposed INN: INDOMETACIN Trade Name: Losec INN or Proposed INN: OMEPRAZOLE MAGNESIUM Trade Name: Viagra Other descriptive name: SILDENAFIL CITRATE Trade Name: Miacalcic Other descriptive name: CALCITONIN (SALMON) Trade Name: Spirix Other descriptive name: SPIRONOLACTONE Trade Name: Esidrix Product Name: Esidrix INN or Proposed INN: HYDROCHLOROTHIAZIDE | Dept. of Pediatrics, The Childrens Hospital, Denver | NULL | Not Recruiting | Female: no Male: yes | 40 | Denmark | |||
| 10 | NCT00478335 (ClinicalTrials.gov) | May 2007 | 23/5/2007 | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Nephrogenic Diabetes Insipidus | Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin | University of Colorado, Denver | University of Aarhus | Completed | 5 Years | 25 Years | Male | 4 | N/A | United States;Denmark |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2006-001202-84-NL (EUCTR) | 01/02/2007 | 31/01/2007 | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Lithium-induced Nephrogenic Diabetes Insipidus MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic | Trade Name: Midamor Product Name: Amiloride Trade Name: Hydrochloorthiazide Product Name: hydrochloorthiazide | Radboud University Nijmegen Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Netherlands | |||
| 12 | NCT00004360 (ClinicalTrials.gov) | September 1995 | 18/10/1999 | Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus | Diabetes Insipidus, Nephrogenic | Drug: chlorothiazide | National Center for Research Resources (NCRR) | Northwestern University | Completed | 6 Months | 70 Years | Both | N/A | NULL |